⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 31, 2024EClinicalMedicineOpen Access

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

Thierry Passeron Khaled Ezzedine Iltefat Hamzavi Nanja van Geel Bethanee J. Schlosser Xiaoqiang Wu Xiaohong Huang Ahmed M. Soliman David Rosmarin John E. Harris Heidi S. Camp Amit G. Pandya

View Full Paper

Ask AI

Bookmark

Share

Abstract

Janus kinase (JAK) inhibition is a promising approach for treating vitiligo. We aimed to assess the efficacy and safety of upadacitinib, an oral selective JAK inhibitor, in adults with non-segmental vitiligo.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Passeron et al. (2024) studied this question.

synapsesocial.com/papers/68e6761db6db6435875fffc3 https://doi.org/10.1016/j.eclinm.2024.102655

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report2025 · 3 citations
2Current role and future scope of upadacitinib in dermatologyClinical Trial · 2026 · 1 citations
3Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence2025 · 7 citations
4Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study2024 · 26 citations
5Treatment of atopic dermatitis with upadacitinib: adcare single center experience2024 · 7 citations

More related papers

Long-term efficacy and safety of oral abrocitinib combined with narrow-band UVB phototherapy in non-segmental vitiligo: a 52-week prospective study2025
Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report2024
Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications2026

More from EClinicalMedicine

The effects of the arts and arts therapies on mental health outcomes of children and young people: a systematic review and meta-analysisThu,
Neighborhood disadvantages and longitudinal progression of multimorbidity among adult survivors of childhood cancer: a single-center St. Jude Lifetime Cohort Study in the U.S.Tue,